Anti-T Antibody

Description:

Dysregulation of cellular glycosylation is a common characteristic of many cancers (1). The T antigen (Galβ1,3-GalNAcα1-O-Ser/Thr ) is up-regulated in a wide variety of cancers (2, 3), and has been investigated as a diagnostic & prognostic marker, and as a therapeutic and vaccine (4, 5). The specificity of the anti-T monoclonal antibody was shown by binding to asialo-fetuin, which presents the T antigen, and not to fetuin, in which the T antigen is capped by sialic acid residues (3). This antibody was previously marketed under HB-T (6).

Hakomori, S. (1996) Cancer Res. 56, 5309.

Springer, G.F. (1984) Science 224, 1198.

Kjeldsen, T. et al. (1988) Cancer Res. 48, 2214.

Desai, P. (2000) Transfusion Med. Rev. 14, 312-25.

Springer, G.F. (1997) J. Mol. Med. 75, 594.

Marcos, N.T. et al. (2004) Cancer Res. 64, 7050.

Preparation: Monoclonal antibodies were produced from the mouse hybridoma 3C9 clone (HB-T).